Efficacy and Safety of Intravenous Tramadol versus Intravenous Paracetamol for Relief of Acute Pain of Primary Dysmenorrhea: A Randomized Controlled Trial
Efficacy and Safety of Intravenous Tramadol versus Intravenous Paracetamol for Relief of Acute Pain of Primary Dysmenorrhea: A Randomized Controlled Trial
复制标题
DOI：
10.1159/000510268
复制
发表时间：
2020-12-01
影响因子：
2.1
通讯作者：
Islam, Yomna
中科院分区：
文献类型：
--
作者：
Ghamry, Nevein Kamal;Ali, Ahmed Said;Islam, Yomna
介绍：许多药物，手术和补充医疗干预用于原发性痛经治疗。然而，对于最有效的干预措施尚未达成共识。目的：比较静脉注射曲马多与静脉注射对乙酰氨基酚缓解原发性痛经急性疼痛的疗效和安全性。研究方法：这项随机对照试验在一家三级转诊医院进行，纳入了100名18至35岁诊断为原发性痛经的患者。患者接受1g扑热息痛或100 mg曲马多溶于100 mL生理盐水，静脉输注10 min。在15、30、60 min和2 h时使用视觉模拟量表测量疼痛强度。我们记录了药物副作用和急救镇痛药的需求。结果：曲马多组在15、30、60 min和2 h的疼痛评分显著低于扑热息痛组（p < 0.001）。与对乙酰氨基酚组相比，曲马多组需要补救镇痛药的患者较少（p = 0.04）。两组之间的副作用无显著差异。结论：静脉注射曲马多在缓解原发性痛经的急性疼痛方面上级静脉注射扑热息痛，且副作用相似。
Introduction: Many pharmaceutical, surgical, and complementary medical interventions are used for primary dysmenorrhea treatment. However, no consensus has been reached about the most effective intervention. Objective: To compare the efficacy and safety of IV tramadol versus IV paracetamol in relieving acute pain of primary dysmenorrhea. Methods: This randomized controlled trial was conducted in a tertiary referral hospital and included 100 patients between 18 and 35 years old diagnosed with primary dysmenorrhea. Patients received either 1-g paracetamol or 100-mg tramadol in 100-mL normal saline as an IV infusion over 10 min. Pain intensity was measured by using a visual analog scale at 15, 30, 60 min, and 2 h. We recorded drug side effects and requirements for rescue analgesics. Results: Pain scores were significantly lower in the tramadol group compared with the paracetamol group at 15, 30, 60 min, and 2 h (p < 0.001). Fewer patients in the tramadol group needed rescue analgesics compared with the paracetamol group (p = 0.04). No significant differences were reported in side effects between both groups. Conclusions: IV tramadol is superior to IV paracetamol in relieving acute pain of primary dysmenorrhea with a comparable side effect profile.